SUPERNUS PHARMACEUTICALS, INC. (SUPN) Form 8-K — Nov 2, 2026
$SUPNForm 8-KItems 1.01, 2.01, 2.03, 3.03, 5.01, 5.03, 7.01, 9.01Filed Nov 2, 2026, 9:28 AM ET0001104659-26-121014Original filing
Supernus Pharmaceuticals completed its merger with Indivior effective November 2, 2026, with each Supernus share converted into 1.5401 shares of Indivior common stock. Supernus is now a wholly owned subsidiary of the combined company, which was renamed Supernus, Inc., and SUPN shares will cease trading on Nasdaq. In connection with the closing, the combined company entered into a $650 million senior secured term loan facility with Citibank, N.A. as agent, priced initially at Term SOFR plus 2.25%.
Key figures
- Debt Amount
- 650000000
- Deal Value Usd
- not stated in this filing (stock-for-stock merger)
- Exchange Ratio
- 1.5401 Indivior shares per Supernus share
- Interest Rate
- Term SOFR + 2.25% (or Base Rate + 1.25%) initially; thereafter SOFR + 2.00%-2.75% based on leverage
- Credit Facility Type
- senior secured term loan facility
- Change Of Control Threshold
- 35% of voting securities of Borrower
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.